PBM or Dry Float Therapy on Sleep Quality in Middle-aged and Elderly

Sponsor
West Virginia University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05963555
Collaborator
(none)
25
1
4
46
0.5

Study Details

Study Description

Brief Summary

The main objective of this study is to assess the impact of implementing photobiomodulation (PBM) therapy, either localized or whole body, or dry float on sleep quality in middle-aged and elderly individuals experiencing sleep disturbance. As a secondary objective we will analyze the effect of the treatments on other indices of recovery (subjective and objective) via physiological monitoring in middle-aged and elderly individuals experiencing sleep disturbance.

The study will have 2 phases: Phase 1 will last 5 weeks and will serve as baseline data collection of sleep quality. Phase 2 contains the experimental conditions and will last 13 weeks. Cognitive, behavioral, and physiological tests will be done at baseline (week 1) and at the end of experimental period (week 18). Sleep tracking data will be collected daily.

Condition or Disease Intervention/Treatment Phase
  • Device: NovoThor
  • Device: VieLight
  • Device: ZeroBody
N/A

Detailed Description

In summary the study participants are expected to:
  • Wear a study provided smart ring (OURA Ring) through the end of the study period (at least 75% of the total study time) which measures sleep quantity/quality.

  • Keep their smart phones nearby and charged while wearing their devices.

  • Complete monthly surveys with questions about general well-being until the end of the study period.

  • Complete a testing battery consisting of cognitive tests, behavioral and mood questionnaires, qEEG and physical assessments, in the beginning and at the end of the study period.

  • Complete the designated experimental condition 2- 3x/week for 12 weeks (at least 75% of the total sessions), if applicable.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
25 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Basic Science
Official Title:
Evaluation of Photobiomodulation or Dry Float Therapy on Sleep Quality in Middle-aged and Elderly Individuals.
Anticipated Study Start Date :
Sep 1, 2023
Anticipated Primary Completion Date :
Jul 1, 2025
Anticipated Study Completion Date :
Jul 1, 2027

Arms and Interventions

Arm Intervention/Treatment
Experimental: Whole-Body Photobiomodulation

Light therapy in both the visible and near-infrared range (non-UV) applied to the whole body in a light pod or bed.

Device: NovoThor
Following the baseline block (first four weeks), participants will use the NovoThor device 2-3 times per week for 20 minute sessions at the WVU Rockefeller Neuroscience Institute.

Experimental: Dry Float

Simulates the effects of traditional Float-REST therapy. Instead of contact with salt water, the dry float system has a very thin membrane that cradles the body and provides a warm sensation, similar to that experienced in a traditional flotation tank.

Device: ZeroBody
Following the baseline block (first four weeks), participants will use the Zerobody device 2-3 times per week for 20 minute sessions at the WVU Rockefeller Neuroscience Institute.

Experimental: Localized Photobiomodulation

Light therapy in both the visible and near-infrared range (non-UV) applied locally to only a specific body region.

Device: VieLight
Following the baseline block (first four weeks), participants will use the VieLight device 2-3 times per week for 20 minute sessions and may be completed at home.

No Intervention: Control

Participants in the control group will be asked to keep their normal daily routine.

Outcome Measures

Primary Outcome Measures

  1. Changes in resting state electroencephalography (EEG) [Changes from baseline versus end of study week 18]

    Electroencephalography (EEG) analysis looking for alterations in brain activity. A paired samples t-Test will be used to compare power activity at baseline and follow-up.

  2. Changes in the Patient Health Questionnaire (PHQ-9) [Changes from baseline versus end of study week 18]

    Participants will complete the Patient Health Questionnaire (PHQ-9) once a month. The higher the score, the more severe the symptoms of depression. Scores range from 5-9 = mild, 10-14 = moderate, 15-19 = moderate severe, 20-27 severe depression

  3. Changes in total sleep via Oura Ring [Changes from baseline versus end of study week 18]

    Oura Ring will be used to track total sleep throughout the study. Increased total sleep values will indicate better quality sleep and decrease total sleep values will indicate poorer sleep.

  4. Changes in the Circadian Sleep Inventory [Changes from baseline versus end of study week 18]

    Evaluate changes in the participants sleeping patterns. Higher values indicate poorer sleep quality.

Eligibility Criteria

Criteria

Ages Eligible for Study:
50 Years to 85 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Male or female between 50-85 years of age

  • Able and willing to give informed consent

  • No significant untreated medical history

Exclusion Criteria:
  • Have no mental or physical conditions that are deemed inappropriate for study participation at investigator's discretion.

Contacts and Locations

Locations

Site City State Country Postal Code
1 WVU Rockefeller Neuroscience Institute Morgantown West Virginia United States 26505

Sponsors and Collaborators

  • West Virginia University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
West Virginia University
ClinicalTrials.gov Identifier:
NCT05963555
Other Study ID Numbers:
  • 2303738136
First Posted:
Jul 27, 2023
Last Update Posted:
Aug 3, 2023
Last Verified:
Jul 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Keywords provided by West Virginia University

Study Results

No Results Posted as of Aug 3, 2023